Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:4919 |
Name | renal pelvis carcinoma |
Definition | |
Source | DiseaseOntology.org |
Alt Ids | DOID:12343 |
Path | disease disease of cellular proliferation cancer organ system cancer urinary system cancer kidney cancer renal pelvis carcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01688999 | Phase II | Cabozantinib | Cabozantinib for Advanced Urothelial Cancer | Completed | USA | 0 |
NCT02608125 | Phase I | PRN1371 | A Dose Escalation Study in Solid Tumors and a Dose Expansion Study of PRN1371 in Adult Patients With Metastatic Urothelial Carcinoma | Terminated | USA | ESP | 0 |
NCT02660034 | Phase I | Pamiparib + Tislelizumab | The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors | Completed | USA | NZL | GBR | FRA | ESP | AUS | 0 |
NCT03355976 | Phase II | Ipilimumab + Nivolumab Nivolumab | BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas | Active, not recruiting | USA | 0 |
NCT03430895 | Phase II | Durvalumab + Tremelimumab | Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract | Completed | USA | 0 |
NCT05756569 | Phase II | Enfortumab vedotin-ejfv + Pembrolizumab | Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology | Recruiting | USA | 0 |
NCT05775471 | Phase II | Enfortumab vedotin-ejfv + Pembrolizumab | Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Cancer | Not yet recruiting | USA | 0 |
NCT06171789 | Phase Ib/II | PRO1107 | PRO1107 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06172478 | Phase II | Patritumab deruxtecan | A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | 2 |